<DOC>
	<DOCNO>NCT02479217</DOCNO>
	<brief_summary>The primary objective study observe safety tolerability Xeloda use medical practice , alone combination docetaxel .</brief_summary>
	<brief_title>Safety Xeloda Solid Tumours</brief_title>
	<detailed_description />
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Metastatic Breast Cancer : woman &gt; =18 year age Patients locally advanced metastatic breast cancer failure cytotoxic chemotherapy . Previous therapy include anthracycline . Patients locally advance metastatic breast cancer failure taxanes anthracyclinecontaining chemotherapy regimen anthracycline therapy indicate . Female patient histopathologically proven metastatic breast cancer Adequate bone marrow , liver , renal cardiac function Colon Cancer : Patients &gt; 18 year age Patients histologicaly confirm colon cancer Patients potential curative tumor resection within 8 week enrolment study Patients previously treat chemiotherapy Metastatic Breast Cancer : Patients previously treat docetaxel ( Taxotere ) capecitabine ( Xeloda ) Patients contraindication study drug list approve SmPC Colon Cancer : Patients previously treat chemiotherapy Patients contraindication study drug list approve SmPC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>